Rifaximin

개요Rifaximin is an antibiotic structurally related to rifamycin. It is reported to be efficacious in the treatment of gastrointestinal infections and hepatic encephalopathy, being highly active against Gram-positive and -negative aerobic and anaerobic bacteria. Due to poor systemic absorption, rifaximin is effective in presurgical sterilization of the GI tract.It displays good activity against a wide spectrum of bacteria, including Salmonella spp., S. aureus, and E. coli.

역사Rifaximin was developed by Salix Pharmaceuticals, it is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of non-infectious gastrointestinal diseases like irritable bowel syndrome and hepatic encephalopathy. Rifaximin was originally approved by the US Food and Drug Administration (FDA) in May of 2004 for the management of traveler's diarrhea caused by noninvasive strains of Escherichia coli in patients aged >12 years. On March 24, 2010, rifaximin received an additional labeling for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients aged ≥18 years with advanced liver disease.

용도Rifaximin is a non-absorbable semisynthetic Rifamycin antibiotic.